返回 A A A Font Size Receive E-mail Alerts Press Releases

Castor™ Gains CFDA Approval

[2017-07-11] 

Shanghai, China - Castor™ Branched Aortic Stent-Graft System ("Castor™"), in-house developed by Shanghai MicroPort Medical (Group) Co., Ltd ("MicroPort®"), recently obtained the regulatory approval from China Food and Drug Administration ("CFDA"). It is the fourth device of MicroPort® that gained the CFDA approval through the CFDA Green Path for innovative medical devices.
 
Castor™ is the first endovascular device used to preserve the branch artery while repair the thoracic aorta. Its unique "unibody design" could accommodate diverse arch anatomy. It is also the world's first branched stent graft system designed for an entirely endovascular treatment of thoracic dissection encroaching the left subclavian artery or the original tear located within 15mm distal to the left subclavian artery and 20mm distal to the left carotid artery. Castor™ adopts the "unibody design", which is sewing the main body and branch stent together to make it possible to deploy and release at the same time. This design innovatively accomplishes deployment and positioning of the unibody branched stent graft, achieving low endoleak rate and better branch artery patency, which reduces the operative trauma and improves safety during the procedure. Castor™ also employs several unique designs, such as kink-free outer sheath design, soft sheath design with excellent arch crossability, and branch stent sheath.
 
Aortic dilation diseases, in particular aortic dissection, are now commonly seen in China with the increasing incidence of atherosclerosis. Aortic dilation diseases are associated with high disability and death rates as they often lead to severe complications such as limb ischemia, visceral ischemia, and paraplegia. It is the emergence of the endovascular repair by stent graft endovascology that largely reduces the operative trauma. Though endovascular repair has become the main method to treat aortic dilation diseases, thoracic aortic dissection involving aortic arch branch artery, such as left subclavian artery, is still the relative contraindication of endovascular repair due to lack of suitable endovascular prosthesis. The launch of Castor™ marks a significant step forward in using endovascular repair to treat aortic arch, making breakthroughs in a key area clinicians have spent many years to research and explore.

About MicroPort®

MicroPort Scientific Corporation (the "Group") is a leading medical device company with business focusing on innovating, manufacturing, and marketing high-quality and high-end medical devices globally. With a diverse portfolio of products now being used at an average rate of one for every 15 seconds in thousands of major hospitals around the world, the Group maintains world-wide operations in a broad range of business segments including Cardiovascular, Orthopedic, Electrophysiological, Endovascular, Neurovascular, Surgical, Diabetes Care and Endocrinal Management, and others. MicroPort® is dedicated to becoming a patient oriented global enterprise improve and reshape patient lives through application of innovative science and technology.

For more information, please refer to: www.microport.com

Forward-Looking Statements

Some information contained on this website contains forward-looking statements. These forward-looking statements include, without limitation, those regarding our future financial position, our strategy, plans, objectives, goals and targets, future developments in the markets where we participate or are seeking to participate, and any statements preceded by, followed by or that include the words "believe", "intend", "expect", anticipate", "project", "estimate", "predict", "is confident", "has confidence" and similar expressions are also intended to identify forward-looking statements. Such statements are based upon the current beliefs and expectations of MicroPort®'s management and are subject to significant risks and uncertainties. MicroPort Scientific Corporation undertakes no obligation to update any of the statements. These forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties and other factors that could cause actual future results to differ materially from current expectations include, but are not limited to, general industry and economic conditions, PRC governmental policies and regulations relating to the medical device manufacturing industry, competition in the medical device manufacturing industry, our ability to develop new products and stay abreast of market trends and technological advances, our goals and strategies, our ability to execute strategic acquisitions of, investments in or alliances with other companies and businesses, fluctuations in general economic and business conditions in China.

This document is for information purposes only and does not constitute or form part of any offer or invitation to sell or the solicitation of an offer or invitation to purchase or subscribe for any securities of MicroPort Scientific Corporation, and no part of it shall form the basis of, or be relied upon in connection with, any agreement, arrangement, contract, commitment or investment decision in relation thereto whatsoever.

All rights reserved.
Copyright © 2017 MicroPort Scientific Corporation

CONTACT:
Amanda Zhang
Corporate Culture & Public Relations Director
Shanghai MicroPort Medical (Group) Co., Ltd. (HQ)
Tel: (86)(21) 38954600-6989
Email: spokesperson@microport.com

 

[Prev]:MicroPort® Endovascular Attends SJVF-2017
[Next]:The Project "Research on a Minimal Invasive, High Efficiency Orthopedic Robotic System" Officially Launched in Shanghai